Immunotherapy for Guillain-Barre syndrome: a systematic review - sprookjes - yvandenbroek - TriplyDB

Immunotherapy for Guillain-Barre syndrome: a systematic review

Immunotherapy for Guillain-Barre syndrome: a systematic review

http://www.wikidata.org/entity/Q22242913

about

Emerging drugs for Guillain-Barré syndrome Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis IVIG treatment and prognosis in Guillain-Barré syndrome Intravenous immunoglobulin for Guillain-Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome Intravenous immunoglobulin for Guillain-Barré syndrome Plasma exchange for Guillain-Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome Health-related quality of life in Guillain-Barré syndrome patients: a systematic review Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.Deaths following vaccination: What does the evidence show?A report of guillain-barré syndrome with myalgia and mild weakness A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination.Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India.Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages.Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.Pathogenesis and treatment of immune-mediated neuropathies.Guillain-barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases.Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata.Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome.Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome.Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome.Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.Immunotherapy in Peripheral Neuropathies Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria.Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.Guillain-Barre syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma Year in review 2011: Critical Care--Neurocritical care.Rapid method for sensitive screening of oligosaccharide epitopes in the lipooligosaccharide from Campylobacter jejuni strains isolated from Guillain-Barré syndrome and Miller Fisher syndrome patients.

P2860

Q22241376-05E3A555-2AA9-485A-A140-B5876502904F Q22251013-2F01F0A6-837C-4CC8-96A7-B5F7685B5495 Q22252627-43B0811D-4A5D-4E86-8A84-A40822324B1F Q24193522-2EC8D64F-9272-473E-9C5D-4F2F330B03E4 Q24200916-2D67D3B6-E6B7-4880-A4DE-E95B18AEF2B3 Q24202100-38D3B1D1-AADD-4D0E-B4EA-A412AE7771DF Q24202179-A6E4B9D2-9946-44CE-B548-77336CA6F16D Q24235600-D0B4D458-B552-4A23-BE58-2959CE59440D Q24236680-031F17A5-968D-47A4-9F16-714852D489A7 Q26864907-23CAE0DE-261D-4A9A-BE55-28FB791B5F34 Q27027324-ABDE1553-6BC4-4F3F-86AF-750AA16A857D Q28306474-119CD774-5B2D-48B5-B2C7-A4F430BBC18C Q28478607-3C8DB124-ECBC-4FF5-A1F9-3A4BCB3234A0 Q30524065-1587E938-6DA5-491C-A7E6-80869E62075C Q33165769-6AAB6EE9-6903-412A-BE07-D8E8EA589B4E Q33757198-5399D4FB-8451-4228-A184-3D7B2CF74D82 Q33868439-318375ED-B2B4-4510-8019-28872044E5C6 Q33882766-25E7719F-3C90-43AD-8B4D-F9F33EF84435 Q33901517-1D3BDACA-0E6E-4076-8C38-D14DDE185207 Q34063671-6D9EC3C2-4C3C-41A6-BE35-CF5C059ADD5C Q34072287-CBA41339-36AA-4B6A-B523-5B5176FCA723 Q34409385-7B45EE88-B927-4BAA-A358-491E1C4691AA Q34443138-26A58B4F-A69B-423C-A32F-0C1D12E18068 Q34619162-E1C028A3-B9E7-42DE-970B-1A6CEE172D00 Q35331829-3CCD2D22-DF6B-40EA-8360-EEBFFC43EFDE Q35705601-EDBC1E55-1ECA-4A37-88BA-6BB64DBBF12A Q35746428-36A74840-EFF0-4D99-AB37-2CE6EF0BC383 Q35751804-9D177580-FF56-436B-AED9-9C63C6B165DD Q35868924-13936BAE-7BB3-4634-AA1C-A10F95B91065 Q35918443-D40F7112-0D68-4599-803F-A0E176CED07B Q36070382-404680ED-ED5D-413C-BF4D-FF4FC42F56AA Q36070406-9329AC2D-B84D-466B-8973-AE5E58A7E3F6 Q36072732-E7AC2DC3-2A3A-4A9B-A809-40A20ED25B9B Q36174702-C06E0080-F06D-42C4-8F02-FB45A9BAFC2D Q36484418-DA66093A-5B8E-4F91-8B5C-853433E0D069 Q36800813-E75D3B7F-5CB9-4681-AD94-FFE5FE6E6BE7 Q36867383-A76CCE5D-97C8-417B-A9E3-FFFC67816B70 Q36894028-E1001D16-D51A-4E70-9001-F93CDF75C813 Q36902672-67CE09B4-9BA2-4E8F-8B20-F04396C3C2DE Q36933438-12CAA96D-84C6-4429-B4CF-A45DFB678388

P2860

Immunotherapy for Guillain-Barre syndrome: a systematic review

http://www.wikidata.org/entity/Q22242913

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Immunotherapy for Guillain-Barre syndrome: a systematic review

@ast

Immunotherapy for Guillain-Barre syndrome: a systematic review

@en

Immunotherapy for Guillain-Barre syndrome: a systematic review

@nl

type

label

Immunotherapy for Guillain-Barre syndrome: a systematic review

@ast

Immunotherapy for Guillain-Barre syndrome: a systematic review

@en

Immunotherapy for Guillain-Barre syndrome: a systematic review

@nl

altLabel

Immunotherapy for Guillain-Barré syndrome: a systematic review

@en

prefLabel

Immunotherapy for Guillain-Barre syndrome: a systematic review

@ast

Immunotherapy for Guillain-Barre syndrome: a systematic review

@en

Immunotherapy for Guillain-Barre syndrome: a systematic review

@nl

P1433

Q22242913-E26A551B-CB9D-4A26-AD33-24461870A783

P1476

Q22242913-313E6A18-673F-4194-9C23-C6A356C78F5F

P2093

Q22242913-25E98D6A-5D08-42CA-884A-C3EBD9EF823D

Q22242913-A6815AF6-27CE-49F1-B8BD-ACEE7421777A

Q22242913-B65A4E7F-2A69-4A27-AECB-8D55A318F22D

Q22242913-BBFBC863-3477-4C8A-AD17-52CCCD6A0115

Q22242913-C4F769B1-28A9-4645-9B37-FC8014AD66C4

Q22242913-D38DA8BA-0529-4D0A-8C9D-A22569DF059C

P304

Q22242913-E7B4769B-0053-44E2-A244-3F3AD31ED8D5

P31

Q22242913-2A88BBCE-AD4B-4BF0-ABC0-82CF57DA7E1E

Q22242913-903C4E67-4BC1-4AE4-844F-C91CF3B04C77

Q22242913-cd305050-f96e-4347-bf99-a9a363fca4a4

P3181

Q22242913-8283DDF1-F69A-4628-B236-ED9F69B87B1E

P356

Q22242913-0F23CA6E-237B-4289-9527-793E2BC4BA50

P407

Q22242913-BE96D246-6148-4E38-B37D-47B2971024C2

P433

Q22242913-5E7D27F5-E646-40C8-BFE2-966789151EC8

P478

Q22242913-204551E2-BA09-4CA5-91ED-7DFBBD848C3D

P577

Q22242913-79C5BD37-ABA8-430B-B19E-D2A12E6EF759

P5875

Q22242913-C6549BFD-FB44-45E8-905A-308289FD22B0

P698

Q22242913-7EEAA8DB-EDA2-4CC7-AA44-127D8FF701C2

P921

Q22242913-1A9A011D-151A-4C9F-8DBE-93B42425ADAF

Q22242913-697AF88D-E0D9-466D-A76D-AB092D2255CF

P3181

P356

P1433

P1476

Immunotherapy for Guillain-Barre syndrome: a systematic review

@en

P2093

A. V. Swan

http://www.w3.org/2001/XMLSchema#string

D. Annane

http://www.w3.org/2001/XMLSchema#string

J.-C. Raphael

http://www.w3.org/2001/XMLSchema#string

P. A. van Doorn

http://www.w3.org/2001/XMLSchema#string

R. A. C. Hughes

http://www.w3.org/2001/XMLSchema#string

R. van Koningsveld

http://www.w3.org/2001/XMLSchema#string

P304

2245-2257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

1897909

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/BRAIN/AWM004

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6470282

http://www.w3.org/2001/XMLSchema#string

P698

17337484

http://www.w3.org/2001/XMLSchema#string

P921

Guillain–Barré Syndrome